The Food & Drug Administration (FDA) has recently approved the game EndeavoRx from Akili Interactive, as the first ever video game therapy to require a prescription, for treating ADHD.
According to an official press release from Akili Interactive, EndeavoRx has been approved by the FDA for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children aged 8-12.
Five clinical studies were performed on over 600 children which “showed EndeavorRx improved objective measures of attention in children with ADHD.” In response to these positive results, the game is will be made available with a prescription after its formal approval by the FDA.
The game is designed to enhance focus and develop cognitive abilities of youth diagnosed with ADHD. You can find the full rundown (via the press release) below.
EndeavorRx is built on the Akili Selective Stimulus Management engine (SSMETM) core technology, a proprietary technology designed for the targeted activation of specific neural systems in the brain to treat diseases with associated cognitive dysfunction. SSME presents specific sensory stimuli and simultaneous motor challenges designed to target and activate the neural systems that play a key role in attention function while using adaptive algorithms to personalize the treatment experience for each individual patient. This enables second by second monitoring of patient progress completing the treatment sessions, and continuously challenges each patient to an optimized level, encouraging patients to improve their performance. Driven by the core belief at Akili that effective medicine can also be fun and engaging, EndeavorRx is delivered through an action video game experience. The captivating experience of EndeavorRx is designed to drive engagement and compliance. […]
Akili is combining scientific and clinical rigor with the ingenuity of the tech and entertainment industries to challenge the status quo of medicine. Akili has pioneered the development of video game-based digital medicine to improve cognitive function. Akili’s flagship product, EndeavorRx, is a prescription digital treatment to address inattention in children with attention deficit hyperactivity disorder (ADHD). Akili’s patented technology serves as the foundation of its products and is designed to directly activate the networks in the brain responsible for cognitive function. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s treatments are delivered through captivating action video game experiences that drive engagement and compliance.
EndeavoRx will be available on iOS with a prescription. More information and prescription facts can be found on the official site.
Image: Akili Interactive